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Significant thrombocytopenia (TCP) commonly occurs in seriously ill patients and after open-heart surgery, possibly as a result of cardiopulmonary bypass, use of 
intraaortic balloon counterpulsation, sepsis, and post-trans-
fusion purpura.1 However, even severe TCP has not been 
clearly linked to a significant worsening in outcomes after 
surgical aortic valve replacement (SAVR).2 Transcatheter 
aortic valve replacement (TAVR) is the standard of care in 
high-risk and intermediate-risk patients with symptomatic 
severe aortic stenosis (AS). Current evidence suggests that 
acquired TCP occurring after TAVR may be due to thien-
opyridine use and extracorporeal circulatory support,3 and 
may be associated with adverse outcomes.4,5 However, few 
data exist regarding clinical outcomes associated with base-
line TCP in patients undergoing TAVR. In a single small 
study, moderate-severe TCP was not associated with mor-
tality, although the study was underpowered.6 Given that 
TAVR is most often performed in elderly subjects, many of 
whom are also frail and have baseline TCP, the aim of this 
study was to evaluate the effect of baseline TCP on clinical 
outcomes after TAVR.
Methods
Data were collected on consecutive patients with severe, 
symptomatic AS undergoing TAVR at Baylor Heart and 
Vascular Hospital (Dallas, Texas) and The Heart Hospital 
Baylor Plano (Plano, Texas) from January 2012 to December 
2015. Baseline demographics, procedural data, and clinical 
outcomes were retrospectively collected and analyzed. For 
the purpose of the current analysis, data from both medi-
cal centers were pooled and a joint database was created. 
The study was approved by the Baylor Institutional Review 
Board. The following definitions were used in accordance 
with the Valve Academic Research Consortium (VARC)-2 
standardized endpoint definitions for TAVR consensus doc-
ument: vascular complication; bleeding; neurological events; 
and acute kidney injury.7 Patients were stratified into two 
groups according to the presence/absence of TCP at base-
line: group 1 = no TCP, defined as platelet counts within 
the “normal” reference range (150 × 109/L to 500 × 109/L); 
group 2 = mild baseline TCP, defined as platelet count 100 
× 109/L to 150 × 109/L; and group 3 = moderate/severe 
baseline TCP, defined as platelet count <100 × 109/L.6 
Primary outcomes of interest of this study were the in-
cidence of all-cause 30-day and 1-year mortality; secondary 
outcomes of interests were procedural complications (acute 
kidney injury, vascular complications, minor and major 
bleeding, stroke/transient ischemic attack), in-hospital mor-
tality, and cardiovascular mortality at 30-day follow-up. 
Statistical analysis. Continuous variables are summa-
rized as mean ± standard deviation or as median and in-
terquartile range (IQR) as appropriate, and were compared 
using Student’s t-test or Mann-Whitney rank-sum test. Cat-
egorical variables were compared using Chi-squared test or 
Fisher’s exact test. Cox regression was used for multivariate 
analysis. For the prediction of 30-day and 1-year all-cause 
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mortality (dependent variables), baseline variables of clinical 
interest and/or satisfaction of the entry criterion of P<.05 in 
the univariable analysis were used as explanatory variables. 
Interaction testing was performed to determine whether 
the effect of TCP was consistent irrespective of Society of 
Thoracic Surgeon (STS) score, age, aortic mean gradient, 
or chronic kidney disease, on the primary endpoints of the 
study. This was performed with likelihood ratio tests of the 
null hypothesis that the interaction coefficient was zero. A 
two-sided alpha level of 0.05 was used for all superiority test-
ing. All statistical analyses were performed using SPSS version 
19 statistical software (SPSS, Inc).8
Table 1. Characteristics of the study population.
All Patients 
(n = 732)
No 
Thrombocytopenia
(>150 x 109/L) 
(n = 571)
Baseline Thrombocytopenia
Mild 
(100-150 x 109/L) 
(n = 131)
Moderate-
Severe 
(<100 x 109/L) 
(n = 30)
P-
Value
Baseline characteristics
   Age (years) 81.8 ± 7.9 81.6 ± 8.1 82.7 ± 7.1 81.4 ± 7.6 .37
   Male gender 395 (54.0%) 280 (49.0%) 89 (67.9%) 26 (86.7%) <.001
   Body mass index (kg/m2) 27.5 ± 6.6 27.8 ± 6.8 26.7 ± 6.1 26.2 ± 5.3 .12
   STS score 7.6 ± 3.8 7.6 ± 3.8 7.2 ± 3.7 8.4 ± 5.3 .45
   Hypertension 598 (82.4%) 470 (83.2%) 103 (78.6%) 25 (83.3%) .46
   Hyperlipidemia 498 (68.9%) 389 (69.0%) 92 (70.2%) 17 (60.7%) .61
   Diabetes 269 (38.2%) 201 (36.6%) 50 (39.1%) 18 (64.3%) .01
   Chronic kidney disease 331 (45.5%) 269 (47.5%) 45 (34.4%) 17 (56.7%) .01
   End-stage renal disease 24 (3.5%) 20 (3.7%) 3 (2.4%) 1 (3.8%) .77
   Coronary artery disease 481 (66.2%) 377 (66.5%) 81 (62.3%) 23 (76.7%) .31
   Peripheral arterial disease 218 (31.1%) 176 (32.1%) 34 (26.8%) 8 (29.6%) .50
   Chronic obstructive pulmonary disease 138 (19.9%) 110 (20.3%) 23 (18.4%) 5 (18.5%) .87
   Atrial fibrillation 218 (29.8%) 166 (29.1%) 42 (32.1%) 10 (33.3%) .58
   Previous CABG/PCI 310 (43.9%) 235 (42.8%) 59 (46.1%) 16 (55.2%) .36
   Previous cerebrovascular accident 124 (18.0%) 104 (19.4%) 17 (13.6%) 3 (11.5%) .22
   Baseline platelet count (x 109/L) 202.6 ± 71.6 225.1 ± 63.1 129.3 ± 13.5 75.9 ± 14.7 <.001
   Nadir platelet count (x 109/L) 128.6 ± 51.5 141.2 ± 49.9 89.3 ± 19.3 53.1 ± 18.7 <.001
Echocardiographic findings
   Left ventricular ejection fraction (%) 54.6 ± 13.4 54.5 ± 13.6 55.0 ± 13.2 56.5 ± 10.9 .67
   Aortic valve mean gradient (mm Hg) 44.7 ± 14.1 44.2 ± 13.5 45.9 ± 13.6 49.7 ± 23.9 .06
   Aortic valve area (mm2) 0.68 ± 0.18 0.68 ± 0.18 0.68 ± 0.21 0.73 ± 0.21 .31
   Right ventricular systolic pressure (mm Hg) 43.3 ± 14.7 43.5 ± 14.7 42.4 ± 12.1 44.1 ± 23.1 .79
Procedural characteristics
   Type of valve .52
      Balloon expandable 440 (60.1%) 349 (61.1%) 73 (55.7%) 18 (60.0%)
      Self expandable 292 (39.9%) 222 (38.9%) 58 (44.3%) 12 (40.0%)
   Approach .70
      Transfemoral 631 (86.2%) 493 (86.3%) 114 (87.0%) 24 (80.0%)
      Transapical 668 (9.2%) 50 (8.8%) 14 (10.7%) 4 (13.3%)
      Transaortic 29 (4.0%) 24 (4.2%) 3 (2.3%) 2 (6.7%)
      Subclavian 4 (0.5%) 4 (0.7%) 0 (0%) 0 (0%)    
Data provided as mean ± standard deviation or number (percentage). 
STS = Society of Thoracic Surgeons; CABG = coronary artery bypass graft surgery; PCI = percutaneous coronary intervention.
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Results
The study population consisted of 732 patients. Baseline 
patient characteristics are summarized in Table 1. The prev-
alence of TCP at baseline was 21.9%, of which 17.9% had 
mild  TCP and 4.0% had moderate/severe TCP. At admission, 
mean platelet count was 202.6 ± 71.6 x 109/L. Mean nadir 
platelet count after TAVR was 128.6 ± 51.5 x 109/L. There 
were no differences in age or procedural characteristics. How-
ever, patients with moderate/severe TCP at baseline were 
more frequently male, and more commonly had diabetes and 
chronic kidney disease. Moreover, in this same patient group, 
the prevalence of liver cirrhosis was 16.7% (5/30), whereas 
in the rest of the population only 4 patients had liver disease 
(4/702; 0.6%). Of the remaining 22 patients with moderate/
severe TCP, 20 were reported to suffer from pancytopenia. 
However, a complete hematological work-up was not avail-
able for every patient. Study subjects were followed for 1 
year after the procedure, with clinical and echocardiographic 
Table 2. Clinical outcomes.
All Patients 
(n = 732)
No 
Thrombocytopenia
(>150 x 109/L) 
(n = 571)
Baseline Thrombocytopenia
Mild 
(100-150 x 109/L) 
(n = 131)
Moderate-
Severe 
(<100 x 109/L) 
(n = 30)
P-
Value
Procedural complications
   Acute kidney injury 11/732 (1.5%) 6 (1.1%) 2 (1.5%) 3 (10.0%) <.001
   Vascular complication 28/732 (3.8%) 23 (4.0%) 3 (2.3%) 2 (6.7%) .46
   Minor bleeding 47/731 (6.4%) 37 (6.5%) 6 (4.6%) 4 (13.3%) .34
   Major bleeding 12/731 (1.6%) 11 (1.9%) 1 (0.8%) 0 (0.0%) .34
   Stroke/transient ischemic attack 18/732 (2.5%) 15 (2.6%) 3 (2.3%) 0 (0.0%) .66
In-hospital mortality 13/732 (1.7%) 8 (1.4%) 1 (0.8%) 4 (13.3%) <.001
30-day cardiovascular mortality 19/732 (2.6%) 12 (2.3%) 1 (0.8%) 5 (16.7%) <.001
30-day all-cause mortality 24/732 (3.3%) 13 (2.3%) 4 (3.1%) 7 (23.3%) <.001
1-year all-cause mortality 70/672 (10.4%) 44 (8.3%) 16 (13.4%) 10 (40.0%) <.001
Data provided as number/total patients with available data (percentage) or number (percentage).
FIGURE 1. Cox proportional model plot for the primary endpoints of all-cause mortality. (A) 30-day survival according to the sever-
ity of thrombocytopenia (TCP) at baseline. (B) 1-year survival according to the severity of TCP at baseline.
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evaluation at 30 days, 6 months, and 12 months; 92.2% of 
the initial population completed 1-year follow-up. Clinical 
outcomes are described in Table 2. Patients with moderate/
severe baseline TCP showed the worst outcomes; indeed, 
moderate/severe TCP at baseline was associated with signifi-
cantly higher 30-day and 1-year all-cause mortality when 
compared to patients with no or mild TCP (23.3% vs 2.3% 
and 3.1% [P<.001] and 40.0% vs 8.3% and 13.4% [P<.001], 
respectively) (Table 2, Figure 1A). Moreover, when compared 
to patients without TCP, patients with baseline moderate/
severe TCP showed an increased rate of in-hospital and 30-
day cardiovascular mortality (13.3% vs 1.4% [P<.001] and 
16.7% vs 2.3% [P<.001], respectively) (Table 2, Figure 1B). 
Procedural complications (vascular complications, minor and 
major bleedings, stroke/transient ischemic attack) were not 
different among groups apart from a higher incidence of 
acute kidney injury in patients with baseline moderate/se-
vere TCP (10.0% vs 1.1%; P<.001) (Table 2). Cox regression 
analysis results for 30-day and 1-year mortality are reported 
in Table 3 and Table 4. Baseline moderate/severe TCP and 
non-transfemoral access were inde-
pendent predictors of 30-day all-
cause mortality (hazard ratio [HR], 
13.18; 95% confidence interval 
[CI], 4.49-38.64 [P<.001] and HR, 
5.15; 95% CI, 1.27-20.97 [P=.02], 
respectively) (Table 3). Baseline 
moderate/severe TCP, non-trans-
femoral access, male gender, and 
chronic kidney disease were inde-
pendent predictors of 1-year all-
cause mortality (HR, 5.90; 95% CI, 
2.68-13 [P<.001]; HR, 7.58; 95% 
CI, 3.12-18.38 [P<.001]; HR, 2.01; 
95% CI, 1.06-3.79 [P=.03]; HR, 
1.88; 95% CI, 1.04-3.39 [P=.04], 
respectively) (Table 4). 
In a subgroup sensitivity analy-
sis in which patients were stratified 
according to presence/absence of 
risk factors (age, STS score, aortic 
mean gradient, chronic kidney dis-
ease), 30-day and 1-year all-cause 
mortality were not affected by the 
tested potential confounders (all in-
teraction P-values >.05) (Figures 2A 
and 2B).
Discussion
This is the largest study of the 
impact of baseline TCP on the ear-
ly and long-term outcomes after 
TAVR with both self-expandable 
and balloon-expandable valves. 
The main findings of this study are the following: (1) base-
line TCP is common (21.9%) in elderly patients undergoing 
TAVR; (2) moderate/severe TCP at baseline, identified by a 
platelet count <100 × 109/L, increases the risk of mortality 
at 30 days and 1 year after TAVR by 13.2-fold and 5.9-fold, 
respectively; and (3) the impaired survival of patients with 
significant TCP is independent from any other risk factor. 
TCP has been widely studied in cardiovascular patients. 
Cardiopulmonary bypass commonly results in a 30%-60% fall 
in platelet count, mainly secondary to hemodilution, platelet 
consumption, and blood loss.1 The rate of TCP after percuta-
neous coronary intervention (PCI) reported in large clinical 
studies is lower (0.7%-13.0%).9 After percutaneous closure 
of congenital heart defects, moderate/severe TCP occurred 
in 11.7%.10 In the setting of SAVR, platelet activation may 
be involved in the mechanism of platelet count decrease.11-13 
Indeed, except for extracorporeal circulation, several steps 
of SAVR that promote platelet activation are present in the 
TAVR procedure, ie, endothelial damage caused by prosthe-
sis implantation, fibrinogen binding on metallic armatures, 
Table 3. Predictors of 30-day all-cause mortality.
Variable
Univariable Analysis Multivariable Analysis
HR (95% CI)  P HR (95% CI) P
Age 1.07 (1.00-1.14) .04 1.06 (0.99-1.15) .11
Male sex 1.01 (0.45-2.28) .99 — —
Chronic kidney disease 3.53 (1.38-9.05) <.01 3.06 (0.97-9.60) .06
Baseline TCP
   Mild 1.35 (0.43-4.13) .60 — —
   Moderate/severe 13.06 (4.46-35.83) <.001 13.18 (4.49-38.64) <.001
Non-transfemoral access 3.06 (1.08-8.62) .04 5.15 (1.27-20.97) .02
RVSP 1.03 (1.01-1.06) .02 1.01 (0.99-1.04) .23
STS score >8 1.12 (0.39-3.19) .83 — —
HR = hazard ratio; CI = confidence interval; RVSP = right ventricular systolic pressure; STS = Society of 
Thoracic Surgeons.
Table 4. Predictors of 1-year all-cause mortality.
Variable
Univariable Analysis Multivariable Analysis
HR (95% CI) P HR (95% CI) P
Age 1.00 (0.97-1.03) .99 — —
Male sex 2.32 (1.35-3.99) <.01 2.01 (1.06-3.79) .03
Chronic kidney disease 2.04 (1.22-3.39) <.01 1.88 (1.04-3.39) .04
Baseline TCP
   Mild 1.71 (0.93-3.15) .08 — —
   Moderate/severe 7.33 (3.11-17.29) <.001 5.90 (2.68-13.02) <.001
Non-transfemoral access 3.83 (1.56-9.68) <.01 7.58 (3.12-18.38) <.001
RVSP 1.02 (1.00-1.04) .02 1.01 (0.99-1.03) .11
STS score >8 1.00 (0.56-1.79) .10 — —
HR = hazard ratio; CI = confidence interval; RVSP = right ventricular systolic pressure; STS = Society of 
Thoracic Surgeons.
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and shear stress modifications due to prosthesis implanta-
tion.14 In the setting of TAVR, TCP has been frequently re-
ported as a common event after the procedure; however, few 
data exist regarding the impact of baseline TCP on outcomes. 
Indeed, the majority of the data reported in literature refer 
to: (1) small populations;4-6,15 (2) patients treated mainly with 
balloon-expandable valves;4-6,16 (3) post-TAVR TCP;5,16 and 
(4) inconsistent effects on in-hospital or 30-day outcomes. 
Flaherty et al6 found no effect of baseline TCP on in-hospital 
mortality in a small study of 90 patients undergoing TAVR. 
Our study is the first large evaluation of baseline TCP in pa-
tients treated with both self-expandable and balloon-expand-
able valves, showing a clear and strong impact of baseline 
TCP on both early and long-term survival. TCP occurring 
early after TAVR (<4 days) is likely related to procedural/
early postprocedural adverse events, such as vascular compli-
cations, bleeding, and multiple blood transfusions, and results 
in a physiological reaction that increases bone marrow pro-
duction of platelets.13 Although postoperative TCP has been 
reported to identify adverse outcomes after TAVR, this only 
happens after the procedure has been performed,5,15 therefore 
limiting its value as a predictor of risk. In our study, pre-
TAVR moderate/severe TCP was associated with a 17.1-fold 
increased risk of death at 30 days and 5.3-fold increased risk 
of death at 1 year. Our data suggest that baseline TCP should 
be considered in determining risk of TAVR, and perhaps 
used in risk calculators. The typical TAVR patient is elderly, 
and low platelet counts may be due to multiple causes (my-
elodysplasia, thrombocytopenic purpura, malignancy, drugs, 
etc), which may explain the worse clinical outcomes of these 
FIGURE 2. Interaction between baseline thrombocytopenia (TCP) and Society of Thoracic Surgeons (STS) score, aortic mean gra-
dient, age, and chronic kidney disease on primary outcomes. (A) Thirty-day all-cause mortality subgroup analysis. (B) One-year 
all-cause mortality subgroup analysis. 
P-Value
<.001
.08
.06
<.001
<.001
.03
<.01
<.001
Adjusted HR (95% CI)
25.94 (4.70-142.9)
6.94 (0.77-62.2)
8.15 (0.91-72.9)
12.55 (3.82-41.2)
10.2 (3.45-30.2)
13.4 (1.21-148.6)
21.3 (3.52-128.9)
8.64 (2.64-28.3)
P (int.)
.37
.95.
.83
.42
P (int.)
.06
.18
.81
.53
P-Value
<.001
.10
.14
<.001
<.001
<.01
<.01
<.001
Adjusted HR (95% CI)
24.08 (7.26-79.7)
3.39 (0.78-14.7)
5.06 (0.59-43.53)
15.9 (5.74-44.03)
7.82 (2.90-21.05)
8.82 (1.71-45.5)
14.45 (2.92-71.43)
7.08 (2.63-19.04)
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patients. It is possible that baseline TCP represents an objec-
tive marker of frailty – a possibility that merits further study. In 
our patient cohort, a subgroup sensitivity analysis showed that 
patients with higher mortality (both at 30 days and at 1 year) 
were those with moderate/severe TCP at baseline, higher STS 
score, older age, and lower aortic mean gradient. 
This study adds to the current knowledge that in patients 
being evaluated for TAVR, a low platelet count (<100 × 
109/L) before the procedure needs to be recognized, since it 
helps identify a subgroup of higher-risk patients. The role of 
baseline TCP needs to be tested in a larger-scale population 
in order to specifically identify the additive value it might 
bring if included in a specific TAVR risk score.
Study limitations. The study design (retrospective and 
observational) carries all the limitations inherent to retro-
spective analyses, especially the inability to determine the 
mechanism of TCP at baseline. There is a fairly high loss to 
follow-up rate; however, 92.2% of the initial patient popula-
tion completed the 1-year follow-up. Additionally, this study 
leaves open questions of how to improve the prognosis of 
patients who have pre-TAVR TCP. 
Conclusion
The impact on daily practice is the following: (1) base-
line TCP represents a strong predictor of mortality in TAVR 
patients, both at short-term and long-term follow-up; (2) 
in patients being evaluated for TAVR, a low platelet count 
before the procedure needs to be recognized, since it helps 
identify a subgroup of higher-risk patients; and (3) baseline 
TCP, which is easy to detect, should be included in ad hoc 
TAVR risk scores.
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